TABLE 1

Pharmacokinetic parameters for taurocholate, digoxin, pravastatin, and rosuvastatin in rats obtained from the literature and a comparison of rat hepatic clearance in vivo (CL_{H, vivo}) with the hepatic clearance predicted from the uptake clearance in SCRH (CL_{H, vitro})

	CL_{H, P}	R_B	CL_{H, vivo}	f_B	CL_{H, vitro} (5 h)	CL_{H, vitro} (96 h)
	ml · min⁻¹ · kg⁻¹		ml · min⁻¹ · kg⁻¹		ml · min⁻¹ · kg⁻¹ (CL_{H, vitro}/CL_{H, vivo} ratio)
Taurocholate	31.4^{^a}	0.6^{^b}	52.3	0.4^{^c}	32.1 (0.615)	5.65 (0.108)
Digoxin	13.3^{^d}	1.04^{^e}	12.7	0.615^{^e}	12.7 (1.00)	7.96 (0.627)
Pravastatin			62^{^f}	1.2^{^f}	29.4 (0.475)	22.5 (0.362)
Rosuvastatin	37.6^{^g}	0.631^{^h}	59.6	0.083^{^h}	16.7 (0.281)	5.21 (0.0874)

CL_{H, P}, in vivo hepatic clearance based on the plasma concentration assessed as the difference between the total plasma clearance and the renal plasma clearance for each compound; R_B, ratio of the blood concentration to the plasma concentration of each compound; f_B, unbound fraction of each compound in the total blood.
a Data from Hayashi and Sugiyama (2007).
b Blood-to-plasma concentration ratio of taurocholate in rats is assumed to be 0.6.
c Data from Inoue et al. (1985).
d Data from Harrison and Gibaldi (1976).
e Data from Liu et al. (2005).
f Data from Watanabe et al. (2010).
g Data from Kitamura et al. (2008).
h Data from Watanabe et al. (2009).